Gender-based mortality follow-up from the program on the surgical control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials: Women in POSCH and other lipid trials

Annals of Surgery

Volumn 224, Issue 4, 1996, Pages 486-500

  Buchwald, Henry ^a,e   Campos, Christian T ^b   Boen, James R ^a   Nguyen, Phuong ^a   Williams, Stanley E ^a   Lau, Joseph ^c   Chalmers, Thomas C ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MetaWorks Inc   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CLOFIBRATE; COLESTIPOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY SURGERY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; CHOLESTEROL; CONTROLLED CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYPERLIPIDEMIAS; ILEUM; MALE; RISK FACTORS; SURVIVAL RATE;

EID: 0029795471     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199610000-00007     Document Type: Article

References (39)

1. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323:946-955.
2. Buchwald H, Campos CT, Matts JP, et al. Women in the POSCH trial. Ann Surg 1992; 216:389-340.
3. Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992; 268:1429-1433.
4. Campos CT, Buchwald H, and the POSCH Group. The Program on the Surgical Control of the Hyperlipidemias (POSCH): demonstration of the beneficial effects of treatment of hypercholesterolemia. Cardiovascular Risk Factors 1992; 2:261-275.
5. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339:563-569.
6. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1995; 231:360-381.
7. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-3240.
8. Brown G, Alpers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
9. Rose GA, Thomson WB, Williams RT. Corn oil in treatment of ischaemic heart disease. Br Med J 1965; 1:1531-1533.
10. Brensike JF Levy RI, Kelsey SR, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69:313-324.
11. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344:633-638.
12. Robins J, Brestow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986; 43:311-323.
13. DerSimonian R, Laird N. Meta-analysis in clinical medicine. Controlled Clin Trials 1986; 7:177-188.
14. SAS Institute Inc. SAS/Stat User's Guide. Version 6, 4th ed. Vol. 2. Cary, NC: SAS Institute Inc; 1989:846.
15. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34:187-220.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
17. Report by a Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Br Med J 1971; 4:775-784.
18. Five-year study by a group of physicians of the Newcastle upon Tyne Region: trial of clofibrate in the treatment of ischaemic heart disease. Br Med J 1971; 4:767-775.
19. Frantz ID Jr, Dawson EA, Ashman PL, et al. Test of effect of lipid lowering by diet on cardiovascular risk: the Minnesota Coronary Survey. Arteriosclerosis 1989; 9:129-135.
20. Frantz ID Jr. Dawson EA, Kuba K, et al. The Minnesota Coronary Survey: effect of diet on cardiovascular events and deaths. Circulation 1975;51(suppl II):4.
21. Dorr AE, Gundersen K, Schneider JC Jr, et al. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chron Dis 1978; 31:5-14.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
23. Pitt B, Mancini BJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26:1133-1139.
24. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
25. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007-3012.
26. Gould KL, Ornish D, Kirkeeide R, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am J Cardiol 1992; 69:845-853.
27. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993; 119:969-976.
28. Hamer AW, White HD. Women and coronary heart disease. New Zealand Med J 1993; 106:176-177.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269:3015-3023.
30. Walsh JME, Grady D. Treatment of hyperlipidemia in women. JAMA 1995; 274:1152-1158.
31. Women's Health Initiative. National Institutes of Health Publications; 1995:95-3771.
32. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction in coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89:975-990.
33. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63:114E-120E.
34. Willerson JT, Golino P, Eidt J, et al. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80:198-205.
35. Woolf N, Davies MJ. Interrelationship between atherosclerosis and thrombosis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, PA: WB Saunders: 1992:41-77.
36. Roberts WC, Buja LM. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction: a study of 107 necropsy patients. Am J Med 1972; 52:425-443.
37. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 761:699-708.
38. Davies MJ, Bland MJ, Hangartner WR, et al. Factors influencing the presence or absence of acute coronary thrombi in sudden ischemic death. Eur Heart J 1989; 10:203-208.
39. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2:941-944.